Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05296629 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
A Phase 3 study of Papulopustular Rosacea, sponsored by Journey Medical Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 323
- Enrollment target
- 20
- Study locations
NCT05296629 is a Phase 3 study of Papulopustular Rosacea that has completed, run by Journey Medical Corporation. The registered enrollment target is 323 participants, above the 250-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT05296629, a Phase 3 study of Papulopustular Rosacea, has completed, sponsored by Journey Medical Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 323 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in a 3:3:2 ratio to DFD-29 (40 mg), Doxycycline capsules 40 mg, or Placebo once daily for 16 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Doxycycline
- DRUG DFD-29
Study Locations (20)
California
- Clinical Trial Site 10 - Cerritos
- Clinical Trial Site 03 - Fremont
- Clinical Trial Site 25 - San Diego
- Clinical Trial Site 29 - San Diego
Florida
- Clinical Trial Site 11 - Clearwater
- Clinical Trial Site 08 - Coral Gables
- Clinical Trial Site 22 - Coral Gables
Michigan
- Clinical Trial Site 18 - Ann Arbor
- Clinical Trial Site 28 - Warren
North Carolina
- Clinical Trial Site 17 - High Point
- Clinical Trial Site 04 - Wilmington
Arkansas
- Clinical Trial Site 05 - Rogers
Indiana
- Clinical Trial Site 02 - Indianapolis
Kansas
- Clinical Trial Site 27 - Overland Park
Massachusetts
- Clinical Trial Site 09 - Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 323 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05296629
The ClinicalTrials.gov registry entry for NCT05296629 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 323 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 250-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (29% higher). The listed sponsor is Journey Medical Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papulopustular Rosacea appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05296629 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Michigan.
Frequently Asked Questions
What is clinical trial NCT05296629 about?
NCT05296629 is a clinical study titled "A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.". This is a 16-week, multicenter, randomized, parallel-group, double-blind, controlled study. After assessing eligibility during a screening period of up to 30 days, approximately 320 subjects at least 18 years old who are diagnosed with moderate to severe papulopustular rosacea will be randomized in ...
What is the current status of trial NCT05296629?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 323 participants. The study started on 2022-03-14. Estimated completion is 2023-06-30.
What conditions does trial NCT05296629 study?
This clinical trial studies the following conditions: Papulopustular Rosacea.
What interventions are being tested in trial NCT05296629?
The interventions under investigation include: Placebo (DRUG), Doxycycline (DRUG), DFD-29 (DRUG).
Who is sponsoring clinical trial NCT05296629?
This trial is sponsored by Journey Medical Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05296629 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
Phase 3 Papulopustular Rosacea Study
COMPLETED · Phase 3
-
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
COMPLETED · Phase 3
-
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
RECRUITING · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.